
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5224308/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine, 2003, 348, 518-527.	27.0	5,264
2	Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 2020, 8, e191-e203.	6.3	2,111
3	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology, The, 2010, 11, 1048-1056.	10.7	2,093
4	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	27.8	1,364
5	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 453-459.	9.1	1,277
6	Cervical Human Papillomavirus Prevalence in 5 Continents: Metaâ€Analysis of 1 Million Women with Normal Cytological Findings. Journal of Infectious Diseases, 2010, 202, 1789-1799.	4.0	1,156
7	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. International Journal of Cancer, 2004, 111, 278-285.	5.1	912
8	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. New England Journal of Medicine, 2002, 346, 1105-1112.	27.0	707
9	Human papillomavirus types in 115,789 HPVâ€positive women: A metaâ€analysis from cervical infection to cancer. International Journal of Cancer, 2012, 131, 2349-2359.	5.1	706
10	Chapter 1: Human Papillomavirus and Cervical CancerBurden and Assessment of Causality. Journal of the National Cancer Institute Monographs, 2003, 2003, 3-13.	2.1	675
11	Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine, 2008, 26, K1-K16.	3.8	658
12	Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2016, 2, 16086.	30.5	615
13	HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncology, The, 2014, 15, 1319-1331.	10.7	581
14	Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. The Lancet Global Health, 2016, 4, e453-e463.	6.3	580
15	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute, 2016, 108, djv403.	6.3	580
16	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. Journal of the National Cancer Institute, 2006, 98, 303-315.	6.3	568
17	Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood, 2008, 111, 4029-4038.	1.4	508
18	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncology, The, 2006, 7, 27-38.	10.7	345

#	Article	IF	CITATIONS
19	Variations in the ageâ€specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer, 2006, 119, 2677-2684.	5.1	332
20	Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer, 2013, 49, 3450-3461.	2.8	320
21	Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium. Clinical Gastroenterology and Hepatology, 2008, 6, 451-458.	4.4	313
22	Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes and Control, 2003, 14, 805-814.	1.8	299
23	Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. International Journal of Cancer, 2015, 136, 98-107.	5.1	296
24	The natural history of human papillomavirus infection. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 2-13.	2.8	280
25	The Epidemiology of Human Papillomavirus Infection and Cervical Cancer. Disease Markers, 2007, 23, 213-227.	1.3	274
26	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	3.8	272
27	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 130-144.	2.1	265
28	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, 11-131.	3.8	261
29	Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer, 2012, 7, 38.	2.6	232
30	Role of Human Papillomavirus in Penile Carcinomas Worldwide. European Urology, 2016, 69, 953-961.	1.9	210
31	EUROGIN 2011 roadmap on prevention and treatment of HPVâ€related disease. International Journal of Cancer, 2012, 131, 1969-1982.	5.1	204
32	Epidemiology and prevention of human papillomavirus and cervical cancer in sub aharan Africa: a comprehensive review. Tropical Medicine and International Health, 2009, 14, 1287-1302.	2.3	194
33	Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression. Vaccine, 2012, 30, F168-F174.	3.8	187
34	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	21.4	179
35	Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. European Journal of Cancer, 2015, 51, 1732-1741.	2.8	172
36	Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet, The, 2017, 389, 861-870.	13.7	171

#	Article	IF	CITATIONS
37	Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV,the, 2018, 5, e45-e58.	4.7	170
38	Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. International Journal of Cancer, 2014, 135, 453-466.	5.1	161
39	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortiu (InterLymph). Blood, 2007, 109, 3479-3488.	m 1. 4	159
40	Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gaceta Sanitaria, 2015, 29, 308-315.	1.5	158
41	HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathology, 2014, 27, 1559-1567.	5.5	156
42	Risk factors of invasive cervical cancer in Mali. International Journal of Epidemiology, 2002, 31, 202-209.	1.9	154
43	Hepatitis C and Risk of Lymphoma: Results of the European Multicenter Case-Control Study EPILYMPH. Gastroenterology, 2006, 131, 1879-1886.	1.3	154
44	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
45	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nature Genetics, 2010, 42, 661-664.	21.4	152
46	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 26-40.	2.1	151
47	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
48	Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. International Journal of Epidemiology, 2008, 37, 536-546.	1.9	141
49	Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups. Journal of the National Cancer Institute, 2012, 104, 240-253.	6.3	141
50	Tumor Necrosis Factor (TNF) and Lymphotoxin-Â (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. American Journal of Epidemiology, 2010, 171, 267-276.	3.4	128
51	Serologic Response to Human Papillomavirus Type 16 (HPV-16) Virus-like Particles in HPV-16 DNA-Positive Invasive Cervical Cancer and Cervical Intraepithelial Neoplasia Grade III Patients and Controls from Colombia and Spain. Journal of Infectious Diseases, 1995, 172, 19-24.	4.0	121
52	Pathogenic role of the eight probably/possibly carcinogenic <scp>HPV</scp> types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. Journal of Pathology, 2014, 234, 441-451.	4.5	119
53	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	6.0	116
54	Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectrum, 2018, 2, pky045.	2.9	115

#	Article	IF	CITATIONS
55	A case-control study of gastric cancer in Venezuela. International Journal of Cancer, 2001, 93, 417-423.	5.1	110
56	The Basaloid Cell is the Best Tissue Marker for Human Papillomavirus in Invasive Penile Squamous Cell Carcinoma: A Study of 202 Cases From Paraguay. American Journal of Surgical Pathology, 2010, 34, 104-114.	3.7	110
57	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World Journal of Urology, 2013, 31, 861-867.	2.2	110
58	The clinical importance of understanding the evolution of papillomaviruses. Trends in Microbiology, 2010, 18, 432-438.	7.7	106
59	Nonâ€Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 2062-2070.	5.1	104
60	Value of p16INK4a in the Pathology of Invasive Penile Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2011, 35, 253-261.	3.7	104
61	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS ONE, 2016, 11, e0147029.	2.5	102
62	Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2008, 167, 1321-1331.	3.4	98
63	Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncology, The, 2011, 12, 1023-1031.	10.7	98
64	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
65	The Occasional Role of Low-risk Human Papillomaviruses 6, 11, 42, 44, and 70 in Anogenital Carcinoma Defined by Laser Capture Microdissection/PCR Methodology. American Journal of Surgical Pathology, 2013, 37, 1299-1310.	3.7	94
66	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
67	Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. International Journal of Cancer, 2002, 98, 155-158.	5.1	92
68	Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: A population-based study. International Journal of Cancer, 2003, 106, 588-593.	5.1	90
69	Distinctive Association of p16INK4a Overexpression With Penile Intraepithelial Neoplasia Depicting Warty and/or Basaloid Features: A Study of 141 Cases Evaluating a New Nomenclature. American Journal of Surgical Pathology, 2010, 34, 385-392.	3.7	88
70	Cervical and anal HPV infections in HIV positive women and men. Virus Research, 2002, 89, 201-211.	2.2	86
71	Atopic Disease and Risk of Non–Hodgkin Lymphoma: An InterLymph Pooled Analysis. Cancer Research, 2009, 69, 6482-6489.	0.9	86
72	IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans. Environmental Health Perspectives, 2015, 123, 507-514.	6.0	86

SILVIA DE SANJOSé

#	Article	IF	CITATIONS
73	Concordance of Prevalence of Human Papillomavirus DNA in Anogenital and Oral Infections in a High-Risk Population. Journal of Clinical Microbiology, 2004, 42, 1330-1332.	3.9	84
74	Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study. Occupational and Environmental Medicine, 2013, 70, 91-98.	2.8	84
75	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 41-51.	2.1	82
76	Chlamydia trachomatis Infection in Female Partners of Circumcised and Uncircumcised Adult Men. American Journal of Epidemiology, 2005, 162, 907-916.	3.4	79
77	Geographic Variation in the Prevalence of Kaposi Sarcoma–Associated Herpesvirus and Risk Factors for Transmission. Journal of Infectious Diseases, 2009, 199, 1449-1456.	4.0	79
78	Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 90-100.	4.5	78
79	Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infectious Agents and Cancer, 2017, 12, 19.	2.6	76
80	Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. British Journal of Cancer, 2019, 121, 954-965.	6.4	76
81	Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: A European multicenter case-control study (Epilymph). International Journal of Cancer, 2006, 119, 901-908.	5.1	75
82	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	12.8	75
83	Human papillomavirus in cervical cancer. Current Oncology Reports, 2002, 4, 175-184.	4.0	74
84	Lack of serological evidence for an association between simian virus 40 and lymphoma. International Journal of Cancer, 2003, 104, 522-524.	5.1	70
85	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 52-65.	2.1	70
86	Coffee during pregnancy: A reproductive hazard?. American Journal of Obstetrics and Gynecology, 1991, 164, 1109-1114.	1.3	68
87	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research, 2008, 68, 10178-10186.	0.9	67
88	Association between Personal Use of Hair Dyes and Lymphoid Neoplasms in Europe. American Journal of Epidemiology, 2006, 164, 47-55.	3.4	65
89	Smoking and Passive Smoking in Cervical Cancer Risk: Pooled Analysis of Couples from the IARC Multicentric Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1379-1390.	2.5	64
90	"Histological characteristics of HPVâ€associated and â€independent squamous cell carcinomas of the vulva: A study of 1,594 casesâ€i International Journal of Cancer, 2017, 141, 2517-2527.	5.1	64

#	Article	IF	CITATIONS
91	Coverage and Factors Associated With Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2008, 12, 82-89.	1.9	61
92	Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. Oral Oncology, 2018, 78, 137-144.	1.5	58
93	New perspectives on screening and early detection of endometrial cancer. International Journal of Cancer, 2019, 145, 3194-3206.	5.1	58
94	Methylation markers <scp><i>FAM19A4</i></scp> and <i><scp>miR124</scp>â€2</i> as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. International Journal of Cancer, 2021, 148, 396-405.	5.1	56
95	Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Human Molecular Genetics, 2007, 16, 3117-3127.	2.9	54
96	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	3.4	54
97	Age at sexual initiation and number of sexual partners in the female Spanish population. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 234-240.	1.1	52
98	Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myelomaa multicentre European case-control study. International Journal of Epidemiology, 2008, 37, 1080-1094.	1.9	52
99	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 1-14.	2.1	52
100	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	2.9	52
101	Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study Epilymph. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1993-2001.	2.5	51
102	Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 134-142.	4.5	49
103	High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sexually Transmitted Infections, 2013, 89, 358-365.	1.9	48
104	Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. International Journal of Cancer, 2014, 135, 88-95.	5.1	48
105	HPV in genital cancers (at the exception of cervical cancer) and anal cancers. Presse Medicale, 2014, 43, e423-e428.	1.9	48
106	Adherence to nutritionâ€based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the <scp>MCC</scp> â€ <scp>S</scp> pain case–control study. International Journal of Cancer, 2017, 141, 83-93.	5.1	48
107	Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. Journal of Pathology, 2012, 228, 534-543.	4.5	47
108	Vaccineâ€related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. International Journal of Cancer, 2008, 122, 1901-1904.	5.1	46

#	Article	IF	CITATIONS
109	Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2379-2388.	2.5	46
110	Association of <scp><i>S</i></scp> <i>treptococcus gallolyticus</i> subspecies <i>gallolyticus</i> with colorectal cancer: Serological evidence. International Journal of Cancer, 2016, 138, 1670-1679.	5.1	46
111	Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. Lancet HIV,the, 2020, 7, e262-e278.	4.7	46
112	Epstein-Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. International Journal of Cancer, 2007, 121, 1806-1812.	5.1	44
113	Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort. International Journal of Cancer, 2014, 135, 440-452.	5.1	44
114	Role of hepatitis C virus infection in malignant lymphoma in Spain. International Journal of Cancer, 2004, 111, 81-85.	5.1	43
115	Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. British Journal of Haematology, 2016, 175, 87-101.	2.5	43
116	Reasons for Receiving or Not Receiving HPV Vaccination in Primary Schoolgirls in Tanzania: A Case Control Study. PLoS ONE, 2012, 7, e45231.	2.5	41
117	Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium. Environmental Health Perspectives, 2016, 124, 396-405.	6.0	41
118	Biological relevance of human papillomaviruses in vulvar cancer. Modern Pathology, 2017, 30, 549-562.	5.5	41
119	Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 45-53.	4.5	41
120	Green spaces, excess weight and obesity in Spain. International Journal of Hygiene and Environmental Health, 2020, 223, 45-55.	4.3	41
121	Basaloid Squamous Cell Carcinoma of the Penis With Papillary Features. American Journal of Surgical Pathology, 2012, 36, 869-875.	3.7	40
122	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	3.8	40
123	<i>FAM19A4/miR124â€2</i> methylation in invasive cervical cancer: A retrospective crossâ€sectional worldwide study. International Journal of Cancer, 2020, 147, 1215-1221.	5.1	40
124	Case-Control Study of Simian Virus 40 and Non-Hodgkin Lymphoma in the United States. Journal of the National Cancer Institute, 2004, 96, 1368-1374.	6.3	39
125	Association of JAKâ€STAT pathway related genes with lymphoma risk: results of a European case–control study (EpiLymph). British Journal of Haematology, 2011, 153, 318-333.	2.5	39
126	Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1313-1318.	2.5	38

#	Article	IF	CITATIONS
127	Reproductive factors and non-Hodgkin lymphoma: A systematic review. Critical Reviews in Oncology/Hematology, 2014, 92, 181-193.	4.4	38
128	Trends in Cancer Incidence in Maputo, Mozambique, 1991–2008. PLoS ONE, 2015, 10, e0130469.	2.5	38
129	Human papillomavirus vaccine disease impact beyond expectations. Current Opinion in Virology, 2019, 39, 16-22.	5.4	38
130	Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiology, 2014, 38, 748-756.	1.9	37
131	Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline. Journal of Global Oncology, 2017, 3, 611-634.	0.5	37
132	Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies. International Journal of Cancer, 2015, 136, 108-116.	5.1	36
133	Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy. Vaccine, 2012, 30, F175-F182.	3.8	35
134	A comprehensive study of polymorphisms in the <i>ABCB1</i> , <i>ABCC2</i> , <i>ABCG2</i> , <i>NR1I2</i> genes and lymphoma risk. International Journal of Cancer, 2012, 131, 803-812.	5.1	35
135	Cervical cancer and herpes simplex virus type 2: Case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. International Journal of Cancer, 1995, 60, 438-442.	5.1	34
136	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. Blood, 2012, 120, 4645-4648.	1.4	34
137	Role of mucosal highâ€risk human papillomavirus types in head and neck cancers in central India. International Journal of Cancer, 2017, 141, 143-151.	5.1	34
138	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.9	34
139	Birth order, allergies and lymphoma risk: Results of the European collaborative research project Epilymph. Leukemia Research, 2007, 31, 1365-1372.	0.8	33
140	Trials and Projects on Cervical Cancer and Human Papillomavirus Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F53-F59.	3.8	33
141	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	3.8	33
142	Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 876-885.	2.5	33
143	Differentiated Vulvar Intraepithelial Neoplasia-like and Lichen Sclerosus-like Lesions in HPV-associated Squamous Cell Carcinomas of the Vulva. American Journal of Surgical Pathology, 2018, 42, 828-835.	3.7	33
144	Introduction of HPV testing for cervical cancer screening in Central America: The Scale-Up project. Preventive Medicine, 2020, 135, 106076.	3.4	33

#	Article	IF	CITATIONS
145	Human papillomavirus distribution in invasive cervical carcinoma in subâ€Saharan Africa: could HIV explain the differences?. Tropical Medicine and International Health, 2012, 17, 1432-1440.	2.3	32
146	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 106-114.	2.1	32
147	Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infectious Agents and Cancer, 2015, 10, 13.	2.6	32
148	Common Infectious Agents and Monoclonal B-Cell Lymphocytosis: A Cross-Sectional Epidemiological Study among Healthy Adults. PLoS ONE, 2012, 7, e52808.	2.5	32
149	Regular use of hair dyes and risk of lymphoma in Spain. International Journal of Epidemiology, 2005, 34, 1118-1122.	1.9	31
150	Rapid acquisition of HPV around the time of sexual debut in adolescent girls in Tanzania. International Journal of Epidemiology, 2016, 45, 762-773.	1.9	31
151	False positive cervical HPV screening test results. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 184-187.	4.5	31
152	Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2019, 219, 1574-1585.	4.0	30
153	NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. Leukemia Research, 2011, 35, 715-720.	0.8	29
154	Recommendations for Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F73-F74.	3.8	29
155	HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus. Cancer Medicine, 2016, 5, 2909-2919.	2.8	29
156	The development of "automated visual evaluation―for cervical cancer screening: The promise and challenges in adapting deepâ€learning for clinical testing. International Journal of Cancer, 2022, 150, 741-752.	5.1	29
157	Difficulty in eradicatingHelicobacter pylori in a population at high risk for stomach cancer in Venezuela. Cancer Causes and Control, 1994, 5, 249-254.	1.8	28
158	Celiac Disease and Lymphoma Risk: A Multicentric Case–Control Study in Spain. Digestive Diseases and Sciences, 2004, 49, 408-412.	2.3	28
159	Analysis ofAurora-A andhMPS1 mitotic kinases in mantle cell lymphoma. International Journal of Cancer, 2006, 118, 357-363.	5.1	28
160	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	1.3	28
161	Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecologic Oncology, 2012, 124, 512-517.	1.4	27
162	Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa. Preventive Medicine, 2018, 114, 205-208.	3.4	27

#	Article	IF	CITATIONS
163	What is needed now for successful scale-up of screening?. Papillomavirus Research (Amsterdam,) Tj ETQq1 1	0.784314 rgBT 4.5	27 27 27
164	Impact of interleukin-10 polymorphisms (1082 and 3575) on the survival of patients with lymphoid neoplasms. Haematologica, 2007, 92, 1475-1481.	3.5	26
165	Genetic Susceptibility to Chronic Lymphocytic Leukemia. Seminars in Hematology, 2013, 50, 296-302.	3.4	26
166	Multiple myeloma and occupation: A pooled analysis by the International Multiple Myeloma Consortium. Cancer Epidemiology, 2013, 37, 300-305.	1.9	26
167	Using HPV prevalence to predict cervical cancer incidence. International Journal of Cancer, 2013, 132, 1895-1900.	5.1	26
168	Human papillomavirus and breast cancer: no evidence of association in a Spanish set of cases. Anticancer Research, 2015, 35, 851-6.	1.1	26
169	Medical history and risk of lymphoma: results of a European case–control study (EPILYMPH). Journal of Cancer Research and Clinical Oncology, 2009, 135, 1099-1107.	2.5	25
170	Inter-observer variation in cytological and histological diagnoses of cervical neoplasia and its epidemiologic implication. Journal of Clinical Epidemiology, 1995, 48, 1167-1174.	5.0	24
171	Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing. Infectious Agents and Cancer, 2020, 15, 61.	2.6	24
172	Human Papillomavirus Types in Invasive Cervical Cancer Specimens From Turkey. International Journal of Gynecological Pathology, 2009, 28, 541-548.	1.4	23
173	Selfâ€reported history of infections and the risk of nonâ€Hodgkin lymphoma: An InterLymph pooled analysis. International Journal of Cancer, 2012, 131, 2342-2348.	5.1	23
174	Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology, 2013, 63, 287-292.	2.9	23
175	Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study. International Journal of Cancer, 2013, 133, 597-603.	5.1	23
176	Hormonal contraception and postmenopausal hormone therapy in Spain. Menopause, 2015, 22, 1138-1146.	2.0	23
177	Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia. , 1996, 66, 70-74.		22
178	Birth Order and Risk of Non-Hodgkin Lymphoma—True Association or Bias?. American Journal of Epidemiology, 2010, 172, 621-630.	3.4	22
179	Methylation of Human Papillomavirus Type 16 CpG Sites at E2-Binding Site 1 (E2BS1), E2BS2, and the Sp1-Binding Site in Cervical Cancer Samples as Determined by High-Resolution Melting Analysis–PCR. Journal of Clinical Microbiology, 2013, 51, 3207-3215.	3.9	22
180	Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer. PLoS ONE, 2012, 7, e47755.	2.5	22

#	Article	IF	CITATIONS
181	Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. Haematologica, 2018, 103, 1881-1888.	3.5	21
182	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes and Control, 2013, 24, 125-134.	1.8	20
183	Prevalence of Human Papillomavirus in Adolescent Girls Before Reported Sexual Debut. Journal of Infectious Diseases, 2014, 210, 837-845.	4.0	20
184	Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. International Journal of Epidemiology, 2016, 45, 728-740.	1.9	20
185	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. Preventive Medicine, 2021, 144, 106438.	3.4	20
186	Biological Convergence of Cancer Signatures. PLoS ONE, 2009, 4, e4544.	2.5	20
187	Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case–control study. Cancer Causes and Control, 2012, 23, 195-206.	1.8	19
188	A Pooled Analysis of Alcohol Consumption and Risk of Multiple Myeloma in the International Multiple Myeloma Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1620-1627.	2.5	19
189	Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial. PLoS ONE, 2017, 12, e0170371.	2.5	19
190	Molecular and pathological basis of <scp>HPV</scp> â€negative cervical adenocarcinoma seen in a global study. International Journal of Cancer, 2020, 147, 2526-2536.	5.1	19
191	Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica, 2004, 89, 1322-31.	3.5	19
192	Clinical evaluation of polymerase chain reaction reverse hybridization assay for detection and identification of human papillomavirus type 16 variants. Journal of Clinical Virology, 2011, 51, 165-169.	3.1	18
193	Night shift work and chronic lymphocytic leukemia in the MCCâ€Spain case–control study. International Journal of Cancer, 2016, 139, 1994-2000.	5.1	18
194	HPV prevalence in vulvar cancer in Austria. Wiener Klinische Wochenschrift, 2017, 129, 805-809.	1.9	18
195	Typeâ€specific human papillomavirus distribution in invasive cervical carcinomas in Paraguay. A study of 432 cases. Journal of Medical Virology, 2012, 84, 1628-1635.	5.0	17
196	A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 631-634.	2.5	17
197	Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition. Clinical Microbiology and Infection, 2022, 28, 315-318.	6.0	17
198	Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. European Journal of Public Health, 2008, 18, 674-680.	0.3	16

SILVIA DE SANJOSé

#	Article	IF	CITATIONS
199	Poor Cervical Cancer Screening Attendance and False Negatives. A Call for Organized Screening. PLoS ONE, 2016, 11, e0161403.	2.5	16
200	Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan. Cancers, 2016, 8, 72.	3.7	16
201	Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph. Haematologica, 2011, 96, 323-327.	3.5	15
202	Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer, 2014, 14, 574.	2.6	15
203	Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70Âyears: the CRICERVA study. BMC Women's Health, 2014, 14, 86.	2.0	15
204	Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study. BMC Public Health, 2017, 17, 194.	2.9	15
205	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	2.7	15
206	Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study. PLoS ONE, 2017, 12, e0184520.	2.5	15
207	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nature Communications, 2018, 9, 4182.	12.8	15
208	Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. BioMed Research International, 2015, 2015, 1-9.	1.9	14
209	Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study. Cancer Epidemiology, 2017, 50, 76-84.	1.9	14
210	Acceptability and safety of thermal ablation for the treatment of precancerous cervical lesions in Honduras. Tropical Medicine and International Health, 2019, 24, 1391-1399.	2.3	14
211	Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide crossâ€sectional study. International Journal of Cancer, 2019, 144, 2478-2488.	5.1	14
212	Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia. PLoS ONE, 2017, 12, e0180480.	2.5	14
213	Common infections with polyomaviruses and herpesviruses and neuropsychological development at 4Âyears of age, the Rhea birth cohort in Crete, Greece. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 1268-1276.	5.2	13
214	The Incidence of Human Papillomavirus in Tanzanian Adolescent Girls Before Reported Sexual Debut. Journal of Adolescent Health, 2016, 58, 295-301.	2.5	13
215	Human papillomavirus 16 is an aetiological factor of scrotal cancer. British Journal of Cancer, 2017, 116, 1218-1222.	6.4	13
216	A functional TNFRSF5 polymorphism and risk of nonâ€Hodgkin lymphoma, a pooled analysis. International Journal of Cancer, 2011, 128, 1481-1485.	5.1	12

SILVIA DE SANJOSé

#	Article	IF	CITATIONS
217	HPV distribution in cervical cancer in Portugal. A retrospective study from 1928 to 2005. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 41-45.	4.5	12
218	Human papillomavirus DNA detected in fingertip, oral and bathroom samples from unvaccinated adolescent girls in Tanzania. Sexually Transmitted Infections, 2019, 95, 374-379.	1.9	12
219	Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study. Cancer Epidemiology, 2020, 64, 101629.	1.9	12
220	Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. European Journal of Nutrition, 2017, 56, 1123-1133.	3.9	11
221	Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2021, 18, 5457.	2.6	10
222	Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infectious Agents and Cancer, 2011, 6, 23.	2.6	9
223	Poor Prognosis Associated With Human Papillomavirus α7ÂGenotypes in Cervical Carcinoma Cannot Be ExplainedÂby Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2013, 85, e223-e229.	0.8	9
224	Evaluation of p16INK4a Overexpression in a Large Series of Cervical Carcinomas. International Journal of Gynecological Pathology, 2014, 33, 74-82.	1.4	9
225	Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study. Journal of General Virology, 2015, 96, 2286-2292.	2.9	9
226	Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology and Radiotherapy, 2018, 23, 484-494.	0.6	9
227	Human Papillomavirus Vaccines and Vaccine Implementation. Women's Health, 2008, 4, 595-604.	1.5	8
228	The Prospects of HPV Vaccination in Cervical Cancer Prevention: Results of a New Independent Trial. Cancer Discovery, 2011, 1, 377-380.	9.4	8
229	Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina. Cancer Epidemiology, 2014, 38, 504-510.	1.9	8
230	Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention. Scientific Reports, 2017, 7, 17208.	3.3	8
231	Epstein Barr virus antibody reactivity and gastric cancer: A population-based case-control study. Cancer Epidemiology, 2019, 61, 79-88.	1.9	8
232	Papillomaviruses and Darwinian classification: response to Van Doorslaer et al Trends in Microbiology, 2011, 19, 50-51.	7.7	7
233	Screening of cervical cancer in Catalonia 2006–2012. Ecancermedicalscience, 2015, 9, 532.	1.1	7
234	Hepatitis C virus seroprevalence in the general female population from 8 countries. Journal of Clinical Virology, 2015, 68, 89-93.	3.1	7

#	Article	IF	CITATIONS
235	The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers. Journal of the National Cancer Institute, 2015, 107, djv128-djv128.	6.3	7
236	Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. Cancer Epidemiology, 2018, 52, 106-111.	1.9	7
237	Prevalence and genotype distribution of cervical human papilomavirus infection in the pre-vaccination era: a population-based study in the Canary Islands. BMJ Open, 2020, 10, e037402.	1.9	7
238	Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women. Infectious Agents and Cancer, 2021, 16, 59.	2.6	7
239	A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 217-221.	2.5	6
240	Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 98-104.	4.5	6
241	Health Outcomes at 1 Year After Thermal Ablation for Cervical Precancer Among Human Papillomavirus– and Visual Inspection With Acetic Acid–Positive Women in Honduras. JCO Global Oncology, 2020, 6, 1565-1573.	1.8	6
242	Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study. PLoS ONE, 2020, 15, e0235658.	2.5	6
243	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	2.8	6
244	Lack of serological evidence for an association between simian virus 40 and lymphoma. International Journal of Cancer, 2003, 107, 507-508.	5.1	5
245	Hepatitis C Infection and Lymphomas: Is There any Benefit in Viral Treatment?. Gastroenterology, 2006, 131, 685-686.	1.3	5
246	Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2020, 17, 5174.	2.6	5
247	Long-term protection of HPV test in women at risk of cervical cancer. PLoS ONE, 2020, 15, e0237988.	2.5	5
248	Oral, genital and anal human papillomavirus infections among female sex workers in Ibadan, Nigeria. PLoS ONE, 2022, 17, e0265269.	2.5	5
249	Concomitant Infection of HIV and HPV: What Are the Consequences?. Current Obstetrics and Gynecology Reports, 2015, 4, 213-219.	0.8	4
250	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Causes and Control, 2019, 30, 889-900.	1.8	4
251	Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women. Preventive Medicine, 2020, 138, 106166.	3.4	4
252	The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study. Archives of Gynecology and Obstetrics, 2020, 301, 753-759.	1.7	4

#	Article	IF	CITATIONS
253	The Epidemiology of Cervical Cancer. , 2012, , 63-83.		3
254	Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Summary. Journal of Oncology Practice, 2017, 13, 452-457.	2.5	3
255	HPV Prevention series. Infectious Agents and Cancer, 2012, 7, 37.	2.6	2
256	Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. Infectious Agents and Cancer, 2015, 10, 5.	2.6	2
257	El cribado del cáncer de cuello de útero en el Sistema Público de Salud de Cataluña. Evaluación y seguimiento durante el perÃodo 2006-2012. Progresos En Obstetricia Y Ginecologia, 2015, 58, 209-220.	0.0	2
258	HPV and Cancer: Epidemiology and Mechanism of Carcinogenesis of the Virus HPV. , 2015, , 143-156.		2
259	Searching beyond the usual papillomavirus suspects in squamous carcinomas of the vulva, penis and head and neck. Infection, Genetics and Evolution, 2016, 45, 198-204.	2.3	2
260	Population-based e-records to evaluate HPV triage of screen-detected atypical squamous cervical lesions in Catalonia, Spain, 2010–15. PLoS ONE, 2018, 13, e0207812.	2.5	2
261	Human DNA decays faster with time than viral dsDNA: an analysis on HPV16 using pathology archive samples spanning 85Âyears. Virology Journal, 2021, 18, 65.	3.4	2
262	Epidemiology of Genitoanal HPV Infections and Associated Cancer. , 2011, , 427-439.		2
263	Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950–1999. Cancer Epidemiology, 2016, 40, 173-178.	1.9	1
264	The Cape Town declaration on human papillomavirus related disease. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 59-60.	4.5	1
265	Insulinâ€like growth factor levels and chronic lymphocytic leukaemia: results from the MCC â€Spain and EpiLymphâ€Spain studies. British Journal of Haematology, 2019, 185, 608-612.	2.5	1
266	Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis. Blood, 2014, 124, 3039-3039.	1.4	1
267	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
268	Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability. Sexually Transmitted Infections, 2022, , sextrans-2021-055303.	1.9	0